Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Jan 02, 2023 11:31am
101 Views
Post# 35199570

RE:What if Denali comes in and scoops up Midatech

RE:What if Denali comes in and scoops up Midatech

No way!

Denali has made their play and they have to play it out. If they bought Bioasis then Denali's share price would drop 90% because the market would rightfully deduce that Denali's technology is inferior to xB3 and that Denali may face a gap of years between the drying up of new TV drugs before anything could come out of the xB3 acquisition. 

And Q-Sphera may not be the big value centre you might think. The steady delivery of drugs, especially to receptors that already have their natural work to do, could impair that natural work through continuous saturation levels of the receptors. On the other hand, the periodic (bi-weekly, say) delivery to, near saturation of, and subsequent desaturation of certain receptors may allow the receptors to take a break through the half-life period of the therapeutic, and then be reengaged through redosing as drug concentration drops. 

But, yes, Q-Sphera may have value, no denying it, but I doubt it's a solution for as many neurodiseases as xB3 is.

But that's not the point. Bioasis has surrendered either because of incompetence or malicious planning. That is the issue. The scientists can work out the science.

Meanwhile, "success conscious" Wall St raiders who know nothing about anything will make the big bucks on it, their own assessment of their great wisdom being refinanced with their own money. 

jd
 

<< Previous
Bullboard Posts
Next >>